New epilepsy treatment options are becoming available to physicians and may help provide safe and effective seizure management in patients for whom traditional drug therapies have been unsuccessful. Presented here is a brief discussion on the screening models used to test drugs for efficacy against various seizure types and the mechanisms of action and pharmacology of antiepilepsy drugs. This is followed by a more detailed review of the clinical pharmacology of the latest three antiepilepsy drugs introduced to the United States: levetiracetam, oxcarbazepine, and zonisamide. All three appear to have advantages over some traditional antiepilepsy drugs and with more clinical experience may replace them in certain seizure types or epilepsy syndromes. (J Child Neurol 2002;17:S58—S64).
Get full access to this article
View all access options for this article.
References
1.
Rho JM, Sankar R.: The pharmacologic basis of antiepileptic drug action. Epilepsia1999;40:1471—1483.
2.
White SH: Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia1999; 40(Suppl 5):S2—S10.
3.
Cloyd JC, Remmel RP: Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy. Pharmacotherapy2000;20(8 Pt 2):1395—1515.
4.
French JA, Gidal BE: Antiepileptic drug interactions. Epilepsia2000;41(Suppl 8):S30-S36.
5.
Bourgeois Bfd : Pharmacokinetic properties of current antiepileptic drugs. What improvements are needed?Neurology2000; 55(Suppl 3):S11—S16.
6.
Klitgaard H. , Matagne A., Gobert J., Wülfert E.: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol1998;353:191—206.
7.
Gower AJ, Hirsch E., Boehrer A., et al: Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res1995;22:207—213.
Dooley M., Plosker GL: Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs2000;60: 871—893.
10.
Jain KK: An assessment of levetiracetam as an anti-epileptic drug. Exp Opin Invest Drugs2000;9:1611—1624.
11.
Pellock J., Glauser T., Bebin M., et al: Single dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy, abstract. Epilepsia1999;40(Suppl 7):A25.
12.
Shorvon S.: Oxcarbazepine: A review. Seizure2000;9:75—79.
13.
McLean MJ, Schmutz M., Wamil AW, et al: Oxcarbazepine: Mechanisms of action. Epilepsia1994;35(Suppl 3):S5—S9.
14.
Glauser TA, Nigro M., Sachdeo R., et al: Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology2000;54:2237—2244.
15.
Barcs G., Walker EB, Elger CE, et al: Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia2000;41:1597—1607.
16.
Beydoun A., Sachdeo RC, Rosenfeld WE, et al: Safety and efficacy of oxcarbazepine monotherapy in patients with uncontrolled partial-onset seizures: A multicenter, double-blind, randomized, parallel-group trial. Neurology2000;54:2245—2251.
17.
Lloyd P., Flesch G., Diderle W.: Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia1994;35(Suppl 3): S10—S13.
Schachter SC: Oxcarbazepine: Current status and clinical applications. Exp Opin Invest Drugs1999;8:1103—1112.
20.
Baruzzi A., Fiorenzo A., Riva R.: Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance. Epilepsia1994;35 (Suppl 3):S14—S19.
21.
Fattore C., Cipolla G., Gatti GL, et al. Induction of ethinylestradiol and levonorgestral metabolism by oxcarbazepine in healthy women. Epilepsia1999;40:783—787.
22.
Jensen PK, Saano V., Haring P., et al. Possible interaction between oxcarbazepine and an oral contraceptive . Epilepsia1992;33: 1149—1152.
23.
Gaily E., Granstrom ML, Liukkonen E.: Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol1997;12:496—498.
24.
Reinikainen KJ, Keränen T., Halonen T., et al: Comparison of oxcarbazepine and carbamazepine: A double-blind study. Epilepsy Res1987;1:284—289.
25.
Dam M., Ekberg R., Loyning Y., et al: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res1989;3:70—76.
Mimaki T.: Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit1998;20:593—597.
28.
Oommen KJ, Matthews S.: Zonisamide: A new antiepileptic drug. Clin Neuropharmacol1999;22:192—200.
29.
Glauser TA, Pellock JM: Zonisamide in pediatric epilepsy: A review of the Japanese experience. J Child Neurol2001;17: in press.
30.
Okada M., Kaneko S., Hirano T., et al: Effects of zonisamide on dopaminergic system. Epilepsy Res1995;22:193—205.
31.
Kochak GM, Page JG, Buchanan RA, et al: Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol1998;38: 166—171.
32.
Yagi K., Seino M.: Open clinical trial of a new antiepileptic drug, zonisamide (ZNA), on 49 patients with refractory epileptic seizures [in Japanese]. J Clin Psychiatry1992;29:111—119.
33.
Faught E.: Review of U.S. clinical trials of zonisamide in treatment of refractory partial-onset seizures, abstract. Epilepsia1999; 40(Suppl 7):94—95.
34.
Kumagai N., Seki T., Yamawaki H., et al: Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatr Neurol1991;45: 357—359.
35.
Glauser TA, Pellock JM: Efficacy and safety of zonisamide in pediatric epilepsy: The Japanese experience, abstract. Epilepsia2000;41(Suppl 7):190.
36.
Shellenberger K., Beck K., Oida T.: Safety of zonisamide in Japanese children, abstract. Epilepsia1999;40(Suppl 7):94.
37.
Wyllie E., Pellock JM: Zonisamide dosing in pediatric patients with epilepsy. Neurology1999;52(Suppl 2):A238.
38.
Data on file. Osaka, Japan, Dainippon Pharmaceuticals Co., Ltd., 2001.
39.
Ohno M., Shimotsuji Y., Abe J., et al: Zonisamide treatment of early infantile epileptic encephalopathy . Pediatr Neurol2000;23:341—344.
40.
Kishi T., Nejihashi Y., Kajiyama M., Ueda K.: Successful zonisamide treatment for infants with hypsarrhythmia. Pediatr Neurol2000;23: 274—277.
41.
Yanai S., Hanai T., Narazaki O.: Treatment of infantile spasms with zonisamide. Brain Dev1999;21:157—161.
42.
Suzuki Y., Nagai T., Ono J., et al: Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia1997;38:1035—1038.
43.
Glauser TA, Pippenger CE: Controversies in blood-level monitoring: Reexamining its role in the treatment of epilepsy. Epilepsia2000;41(Suppl 8):S6—S15.
